Moleculin CEO Highlights Preliminary Unblinded Efficacy Results From First 45 Patients Enrolled In Part A Of Pivotal Phase 2/3 MIRACLE Trial
Moleculin Biotech, Inc., (NASDAQ: MBRX ) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What This Means" segment. For the segment, Chairman and CEO Wally Klemp discusses the positive preliminary unblinded efficacy